HR+/HER2- Breast Cancer
Conditions
Keywords
neoadjuvant, HR+/HER2- breast cancer, CDK4/6 inhibitors
Brief summary
This is a single arm, open label, phase 2 trial aimed to investigate the effects and safety of neoadjuvant CDK4/6 inhibitors in combination with endocrine for HR+/HER2- breast cancer. A total of 40 patients with stage II-III HR+/HER2- breast cancer will be enrolled. Six 4-week cycles of adjuvant therapy will be administrated.Premenopausal or perimenopausal patients should combine ovarian function suppression, including bilateral oophorectomy or treatment with gonadotropin-releasing hormone agonists.
Interventions
DRUGCDK4/6 inhibitors+Endocrine Therapy
CDK4/6 inhibitors：dalpiciclib,palbociclib,abemaciclib,ribociclib
Sponsors
Xinhong Wu, PhD
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* 1\. Age ≥18 years old. 2\. Premenopausal and postmenopausal women or men with stage II-III disease (multifocal and/or multifocal early invasive breast cancer) if all tumors on histopathological examination meet the pathological criteria for ER and/or PR \> 10% and HER2- (HER2 expression of 0 or 1+ or 2+ and negative FISH test). 3.Patients had to have histologically confirmed ER and (or PR\>10%, HER2 -, early-stage invasive disease. 4.Intolerance or insensitivity to neoadjuvant chemotherapy: 2 cycles of neoadjuvant chemotherapy, PD/SD according to tumor evaluation, old age, and basic diseases can not tolerate chemotherapy. 5\. ECOG PS score 0-2. 6\. Patients must be able and willing to swallow and retain oral medications. 7\. In premenopausal women, a serum or urine pregnancy test had to be negative within 14 days of enrollment or in women who had been amenorrhea for less than 12 months at enrollment. 8.Patients who had received neoadjuvant endocrine therapy were eligible if they were enrolled within 6 months of the initial histologic diagnosis and had completed no more than 2 months of neoadjuvant endocrine therapy. 9\. Absolute neutrophil count ≥1500/µL, platelet ≥100000/mm3, hemoglobin ≥10g/dL
Exclusion criteria
* 1\. Prior treatment with any CDK4/6 inhibitor. 2\. Inflammatory or stage IV or bilateral breast cancer. 3\. History of allergic reactions caused by chemical or biological components similar to CDK4/6 inhibitors. Patients who received any drugs or substances that were effective CYP3A isoenzyme inhibitors or inducers within 7 days of enrollment. 5\. Uncontrolled coexisting medical conditions may limit adherence to study requirements. 6\. Pregnant women with a negative pregnancy test within 14 days before admission or women of childbearing potential. 7\. Patients with a history of any malignancy were not eligible. 8\. Patients receiving endocrine therapy within 5 years before diagnosis of current malignancy.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Objective Response Rate (ORR) | up to 24 weeks | ORR is defined as proportion of patients demonstrating either a partial response (PR) or a complete response (CR) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| change in Ki67 | up to 24 weeks | change in Ki67 from baseline to end of treatment |
| complete cell cycle arrest | up to 4 weeks | The proportion of patients with Ki-67≤2.7% on day 15 of cycle 1 treatment |
| Invasive disease free survival（iDFS） | up to 3 years | Time from adjuvant therapy to disease recurrence in patients with invasive disease |
Countries
China
Outcome results
None listed